日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Treatment and survival of patients diagnosed with high-risk HR+/HER2- breast cancer in the Netherlands: a population-based retrospective cohort study

荷兰高危HR+/HER2-乳腺癌患者的治疗和生存情况：一项基于人群的回顾性队列研究

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2024.103008
Lammers, S W M; Meegdes, M; Vriens, I J H; Voogd, A C; de Munck, L; van Nijnatten, T J A; Keymeulen, K B M I; Tjan-Heijnen, V C G; Geurts, S M E
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2024
文献求助 收藏

The prognostic impact of BMI in patients with HR+/HER2- advanced breast cancer: a study of the SONABRE registry

BMI对HR+/HER2-晚期乳腺癌患者预后的影响：一项基于SONABRE注册研究的分析

期刊:Breast Cancer Research and Treatment
影响因子:3
doi:10.1007/s10549-023-07108-6
Lammers, Senna W M; Thurisch, Hannah; Vriens, Ingeborg J H; Meegdes, Marissa; Engelen, Sanne M E; Erdkamp, Frans L G; Dercksen, M Wouter; Vriens, Birgit E P J; Aaldering, Kirsten N A; Pepels, Manon J A E; van de Winkel, Linda M H; Peters, Natascha A J B; Tol, Jolien; Heijns, Joan B; van de Wouw, Agnes J; Teeuwen, Nathalie J A; Geurts, Sandra M E; Tjan-Heijnen, Vivianne C G
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2024
文献求助 收藏

Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+ metastatic breast cancer: an analysis of the SONABRE registry

SONABRE注册研究分析了新诊断为HER2阳性转移性乳腺癌患者的真实世界治疗模式和生存期的时间趋势。

期刊:Breast Cancer Research and Treatment
影响因子:3
doi:10.1007/s10549-023-07235-0
Geurts, Sandra M E; Ibragimova, Khava I E; Ding, Nan; Meegdes, Marissa; Erdkamp, Frans; Heijns, Joan B; Tol, Jolien; Vriens, Birgit E P J; Dercksen, Marcus W; Aaldering, Kirsten N A; Pepels, Manon J A E; van de Winkel, Linda; Peters, Natascha A J B; van de Wouw, Agnes J; Maaskant, Sabrina A J G; Teeuwen-Dedroog, Nathalie J A; van Nijnatten, Thiemo J A; de Boer, Maaike; Tjan-Heijnen, Vivianne C G
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2024
文献求助 收藏

Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry

HER2阳性晚期乳腺癌患者前四线治疗的疗效：来自SONABRE注册研究的结果

期刊:Breast Cancer Research and Treatment
影响因子:3
doi:10.1007/s10549-022-06832-9
Ibragimova, Khava I E; Geurts, Sandra M E; Meegdes, Marissa; Erdkamp, Frans; Heijns, Joan B; Tol, Jolien; Vriens, Birgit E P J; Dercksen, Marcus W; Aaldering, Kirsten N A; Pepels, Manon J A E; van de Winkel, Linda; Peters, Natascha A J B; Teeuwen-Dedroog, Nathalie J A; Vriens, Ingeborg J H; Tjan-Heijnen, Vivianne C G
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2023
文献求助 收藏

The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2- advanced breast cancer patients: A study of the Dutch SONABRE Registry

CDK 4/6抑制剂的应用及其对HR+/HER2-晚期乳腺癌患者治疗选择的影响：一项来自荷兰SONABRE注册研究

期刊:International Journal of Cancer
影响因子:4.7
doi:10.1002/ijc.33785
Meegdes, Marissa; Geurts, Sandra M E; Erdkamp, Frans L G; Dercksen, Marcus Wouter; Vriens, Birgit E P J; Aaldering, Kirsten N A; Pepels, Manon J A E; van de Winkel, Linda M H; Teeuwen, Nathalie J A; de Boer, Maaike; Tjan-Heijnen, Vivianne C G
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2022
文献求助 收藏

The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry

初始激素受体/HER2亚型是晚期乳腺癌亚型不一致的主要决定因素：一项基于SONABRE登记研究的调查。

期刊:Breast Cancer Research and Treatment
影响因子:3
doi:10.1007/s10549-021-06472-5
Meegdes, Marissa; Ibragimova, Khava I E; Lobbezoo, Dorien J A; Vriens, Ingeborg J H; Kooreman, Loes F S; Erdkamp, Frans L G; Dercksen, M Wouter; Vriens, Birgit E P J; Aaldering, Kirsten N A; Pepels, Manon J A E; van de Winkel, Linda M H; Tol, Jolien; Heijns, Joan B; van de Wouw, Agnes J; Peters, Natascha A J B; Hochstenbach-Waelen, Ananda; Smidt, Marjolein L; Geurts, Sandra M E; Tjan-Heijnen, Vivianne C G
肿瘤
HER2
肿瘤免疫
信号转导
乳腺癌
免疫/内分泌
发表日期：2022
文献求助 收藏